Research and Technology Management

Similar documents
Research and Technology Management

Clinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants)

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

Key ASCO Presentations Issue 2, Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases

Summary of Research and Writing Activities in Oncology

National Cancer Drugs Fund List - Approved

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona

Oncology Pipeline Analytics

CLINICAL TRIALS ACC. Jul 2016

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

Qué hemos aprendido hasta hoy? What have we learned so far?

Clinical Therapeutic Intelligence Report: Year in Review

Curriculum Vitae ARUN K. KALRA, MD

Forward-Looking Statements

Citi Global Healthcare Conference

(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018

Rationale Design of Combination Therapy in Prostate Cancer: Targeting the AR and PI3K pathways

SKCC Protocol Review Committee New Study Application

The 2015 donations will be transformative:

Rational combinations with immunotherapeutics

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)

To register or to learn more please visit:

Selumetinib (AZD6244; ARRY ) Pediatric MATCH. George Kirk June 2016

Changes from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150

Relapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma

Summary of Strategic Competitive Analysis and Publication Planning

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Immuno-Oncology Applications

Open clinical uro-oncology trials in Canada

A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL

Project Data Sphere : Progress & Promise Single-arm Trials in Cancer Drug Evaluation Workshop. June 30, 2016 Martin J. Murphy, DMedSC, PhD, FASCO

Progress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT

Histology independent indications in Oncology

CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of )

Opdivo. Opdivo (nivolumab) Description

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

NCCN Guidelines for Central Nervous System Cancers V Follow-Up on 02/23/18

SUPPLEMENTARY INFORMATION

Bevacizumab (Bev) with Chemotherapy, Followed by Bev, in the Treatment of Newly Diagnosed and Platinum- Sensitive Recurrent Ovarian Cancer

Patient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:

Special Situation: Brain metastases

BLA /S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL

New Biological Insights and Recent Therapeutic Advances in the Management of Lung Cancer

Highlights of these abstracts are presented below:

PTAC meeting held on 5 & 6 May (minutes for web publishing)

Key ASH Presentations Issue 2, Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL)

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD

Recent Surge in FDA Approvals Shakes up the Oncology Promotional Landscape. Perjeta. Stivarga. Marquibo. Bosulif. Xtandi. Krypolis.

We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications

Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer

Oncology Grand Rounds Series:

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

JAK AND PI3K SIGNALING PATHWAY MARKETS

Histology: Its Influence on Therapeutic Decision Making

A View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.

Oncology Market Forecast To 2013

PRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES

ESMO Symposium on Immuno-Oncology Programme book

Attached from the following page is the press release made by BMS for your information.

Repurposed RET Inhibitors : poor RET coverage in humans MKI Approved Dose Toxicities

NCCN Non Small Cell Lung Cancer V Meeting July 8, 2016

PI3K/mTOR Dual Inhibitor

Supplemental Table 1.1: Prostate cancer prognostic tools

First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC)

The legally binding text is the original French version

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor

All Studies by Indication

Critical Pathways in Breast Cancer Treatment

Statistical validation of biomarkers and surogate endpoints

Open clinical uro-oncology trials in Canada

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

Summary... 2 SARCOMA Neoadjuvant chemotherapy in patients with localised high-risk STS... 3

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B

2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 19-21, 2016

Clinical: Ipilimumab (MDX-010) Update and Next Steps

Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES

Oral Chemotherapy Agents

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic

New Prognostic Markers in Acute Myeloid Leukemia (AML)

MEDICAL PRIOR AUTHORIZATION

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 25-27, 2017

Equity Research. Infinity Pharmaceuticals, Inc. (INFI-NSDQ) INFI: balanced risk/reward profile, maintaining a HOLD rating. OUTLOOK SUMMARY DATA

SU2C TOP SCIENCE ACCOMPLISHMENTS

CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017)

Opdivo. Opdivo (nivolumab) Description

Master Protocols for Immunotherapy Combinations

Immunotherapy Approaches in Lymphoma

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Title Cancer Drug Phase Status

Transcription:

Office of Technology Development - Sponsored Research Agreements Join us as we congratulate the Principal Investigators of new industry sponsored research agreements listed below: January 2012 Principal Investigator: Ingo K. Mellinghoff, MD Department/Program: Neurology/Neurology Service Project Title: Phase II Study of BKM120 for Patients with Recurrent Glioblastoma and Activated P13K Pathway Total Award Amount: $265,120 Award Date: 01/18/12 Awarding Agency: Dana-Farber/Partners CancerCare, Inc. Principal Investigator: Alison J. Moskowitz, MD Department/Program: Medicine/Lymphoma Service Project Title: Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients with Relapsed or Refractory Hodgkin Lymphoma Total Award Amount: $497,157.04 Award Date: 01/04/12 Awarding Agency: Seattle Genetics, Inc. Principal Investigator: Gary Schwartz, MD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: A Phase I Study of AEB071, An Oral Protein Kinase C Inhibitor, in Patient with Metastatic Uveal Melanoma Total Award Amount: $772,241.17 Award Date: 01/06/12 Awarding Agency: Novartis Pharmaceuticals Corporation February 2012 Principal Investigator: Martee L. Hensley, MD Department/Program: Gynecologic Medical Oncology Project Title: A Randomized Controlled Study of Yondelis (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated with An Anthracycline and Ifosfamide Total Award Amount: $190,200 Award Date: 02/07/12 Awarding Agency: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Principal Investigator: Peter Kijewski, PhD Department/Program: Imaging & Spectroscopic Physics Project Title: CRA GE Kijewski 1 Memorial Sloan- Kettering Cancer Center

Total Award Amount: $42,642 Award Date: 02/20/12 Awarding Agency: GE Healthcare Principal Investigator: Nikoletta Lendvai, MD, PhD Department/Program: Medicine/Hematology Service/Lymphoma Service Project Title: Phase 2 Study of Canfosfamide HCI for Injection (TELCYTA) in Combination in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Difuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM) Total Award Amount: $116,411 Award Date: 02/15/12 Awarding Agency: Telik, Inc. Principal Investigator: Michael Morris, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: A Phase I, Open-Label, Multicengre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of Ascending Doses of AZD3514 in Patients with Metastatic Castration-Resistant Prostate Cancer Total Award Amount: $281,834 Award Date: 02/13/12 Awarding Agency: AstraZeneca Principal Investigator: Eileen O'Reilly, MD Department/Program: Medicine/Gastrointestinal Oncology Service Project Title: Retrospective Study of BRCA and P ALB2 Mutations and HR Deficiency in Pancreatic Cancer Total Award Amount: $20,850 Award Date: 02/20/12 Awarding Agency: Myriad Genetics Inc. Principal Investigator: Paul Paik, MD Department/Program: Medicine Project Title: A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of Ascending Doses of AZD4547 in Patients with Advanced Solid Malignancies Total Award Amount: $219,400 Award Date: 02/02/12 Awarding Agency: Astra Zeneca Inc. Principal Investigator: Dana Rathkopf, MD, PhD Department/Program: Medicine / Genitourinary Oncology Service Project Title: Investigator Initiated Study: Establishing a Neo-Adjuvant Platform for Developing Targeted Agents: Degarelix Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer. Total Award Amount: $221,596 2 Memorial Sloan- Kettering Cancer Center

Award Date: 02/21/12 Awarding Agency: Ferring Pharmaceuticals Principal Investigator: Gregory J. Riely, MD, PhD Department/Program: Medicine/Thoracic Oncology Service Project Title: A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects with Advanced Non-Small Cell Lung Cancer and BRAF Mutations Total Award Amount: $211,373 Award Date: 02/07/12 Awarding Agency: GlaxoSmithKline/ICON Clinical Research, Inc. Principal Investigator: Naiyer A. Rizvi, MD Department/Program: Medicine/Thoracic Oncology Service Project Title: A Multi-Arm Phase I Study of BMS-936558 in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in Subjects with Treatment-Naive Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) Total Award Amount: $403,435 Award Date: 02/01/12 Awarding Agency: Bristol-Myers Squibb Principal Investigator: William D. Tap, MD Department/Program: Melanoma and Sarcoma Service Project Title: A Randomized Phase 3, Multicenter, Open Labeled Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unressectable or Metastatic Soft Tissue Sarcoma Total Award Amount: $639,646 Award Date: 02/20/12 Awarding Agency: Threshold Pharmaceuticals/Sarcoma Alliance for Research Through Collaboration Principal Investigator: Yi-Wei Tang, MD, PhD, F(AAM), FIDSA Department/Program: Clinical Microbiology Project Title: SRA ACEA Biosciences Tang icelldx Total Award Amount: $32,500 Award Date: 02/25/12 Awarding Agency: ACEA Biosciences, Inc. March 2012 Principal Investigator: Dean F. Bajorin, MD Department/Program: Medicine/Genitourinary Oncology Project Title: Phase II Study of BKM120 in Metastatic Transitional cell Carcinoma of the Urothelium Total Award Amount: $109,469 3 Memorial Sloan- Kettering Cancer Center

Award Date: 03/07/12 Awarding Agency: Novartis Pharmaceuticals Corporation Principal Investigator: Jennifer Hay, PhD Department/Program: Psychiatry & Behavioral Sciences Project Title: Assessment of MAPK Pathway Activity in PBMCs Collected from Melanoma Patients Per and During Treatment with BMS-908662 Total Award Amount: $16,000 Award Date: 03/16/12 Awarding Agency: Bristol-Myers Squibb Principal Investigator: Jennifer Hay, PhD Department/Program: Psychiatry & Behavioral Sciences Project Title: Ipilimumab Treatment Kinetics: An Evaluation of Patient Perceptions and Quality of Life Total Award Amount: $16,000 Award Date: 03/16/12 Awarding Agency: Bristol-Myers Squibb Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Project Title: Coordinating Center Service Agreement Total Award Amount: $48,315 Award Date: 03/13/12 Awarding Agency: Agensys Inc. May 2012 Principal Investigator: Jason S. Lewis, PhD Department/Program: Radiology/Radiochemistry Service Project Title: SRA ContraFect Lewis Biodist Total Award Amount: $7,633.23 Award Date: 05/01/12 Awarding Agency: ContraFect Principal Investigator: Jedd D. Wolchok, MD, PhD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: Clinical Research Support Agreement for Study Protocol BRA116254 Total Award Amount: $57,400 Award Date: 05/08/12 Awarding Agency: GlaxoSmithKline June 2012 Principal Investigator: Ross Levine, MD 4 Memorial Sloan- Kettering Cancer Center

Department/Program: Medicine/Human Oncology & Pathogenesis Program (HOPP) Project Title: Development of Sensitive Pharmacodynamic Assays, Including Jak2 Phosphorylation Assays, for MPN Patients Total Award Amount: $80,000 Award Date: 06/25/12 Awarding Agency: Sanofi-Aventis US Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: SRA Exellxis Scher CTC project for their phase III pain endpoint study Total Award Amount: $545,093 Award Date: 06/11/12 Awarding Agency: Exelixis, Inc. August 2012 Principal Investigator: Jorge A. Carrasquillo, MD Department/Program: Radiology/Nuclear Medicine Project Title: SRA GILEAD Larson GS-6624 with I-124 Total Award Amount: $76,838 Award Date: 08/10/12 Awarding Agency: Gilead Sciences Principal Investigator: Jorge A. Carrasquillo, MD Department/Program: Radiology/Nuclear Medicine Project Title: To Improve Immunotherapy of Human Melanoma by 20D7S PET Imaging Total Award Amount: $135,762 Award Date: 08/10/12 Awarding Agency: ImClone Systems, Inc. Principal Investigator: Neal Rosen, MD, PhD Department/Program: Medicine/Breast Cancer Medicine/Molecular Pharmacology & Chemistry Project Title: SRA Merck Rosen SCH772984 Total Award Amount: $101,465 Award Date: 08/21/12 Awarding Agency: Merck & Co September 2012 Principal Investigator: Joseph P. Erinjeri, MD, PhD Department/Program: Radiology/Interventional Radiology Project Title: Optical Assessment of Intracellular Signaling Pathways in Live Cells Obtained A tier Percutaneous Needle Biopsy Using Dynamic Mass Redistribution 5 Memorial Sloan- Kettering Cancer Center

Total Award Amount: $41,990 Award Date: 09/05/12 Awarding Agency: Corning Incorporated Principal Investigator: Gary Ulaner, MD, PhD Department/Program: Radiology Project Title: FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients Total Award Amount: $78,000 Award Date: 09/25/12 Awarding Agency: General Electric Principal Investigator: James A. Fagin, MD Department/Program: Human Oncology & Pathogenesis Program (HOPP) Project Title: SRA AZ Project 56 Fagin Total Award Amount: $125,723 Award Date: 09/06/12 Awarding Agency: Dana-Farber/Partners CancerCare, Inc. October 2012 Principal Investigator: Mark Dunphy, DO Department/Program: Nuclear Medicine Project Title: PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study Total Award Amount: $471,064.44 Award Date: 10/18/12 Awarding Agency: Samus Therapeutics LLC Principal Investigator: Vincent Laudone, MD Department/Program: Surgery/Urology Project Title: MTA In GE Laudone Determine the Feasibility and Scope of a Collaborative Joint Development Program Using GE Proprietary Myelin-Binding Fluorophore and Compact Instrumentation for Open and Minimally Invasive Surgeries Total Award Amount: $11,214 Award Date: 10/05/12 Awarding Agency: General Electric Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Project Title: CTC Lab Service Agreement Genentech Scher and Fleisher Total Award Amount: $189,537 Award Date: 10/15/12 Awarding Agency: Genentech, Inc. November 2012 6 Memorial Sloan- Kettering Cancer Center

Principal Investigator: David Finley, MD Department/Program: Thoracic Service Project Title: Cardiopulmonary Effects of Airway Spray Cryotherapy Total Award Amount: $152,500 Award Date: 11/30/12 Awarding Agency: CSA Medical, Inc. December 2012 Principal Investigator: Jedd D. Wolchok, MD, PhD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: 2012 Celgene Future leader in Hematology Award for Clinical Research in Hematology Total Award Amount: $ $7,407.41 Award Date: 12/03/12 Awarding Agency: Celgene Corporation Principal Investigator: James Eastham, MD Department/Program: Surgery/Urology Project Title: Sponsored Research Agreement between Exosome Diagnostics, Inc. and MSKCC Total Award Amount: $34,134 Award Date: 12/11/12 Awarding Agency: Exosome Diagnostics, Inc Principal Investigator: Malcolm Moore, DPhil Department/Program: Medicine/Division of Hematologic Oncology/Cell Biology Project Title: Arion Sponsored Research Total Award Amount: $177,803 Award Date: 12/31/12 Awarding Agency: Arion Pharmaceuticals 7 Memorial Sloan- Kettering Cancer Center